Lixte Biotechnology Holdings

Lixte Biotechnology Holdings is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs that can treat cancer more effectively. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target these in animal models. The current drug portfolio includes serine/threonine protein phosphatase inhibitors, which are crucial for cell division and DNA damage repair, as well as histone deacetylase inhibitors that modulate gene expression and protein degradation pathways.